Key Insights

Highlights

Success Rate

92% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

4.4%

2 terminated out of 45 trials

Success Rate

92.3%

+5.8% vs benchmark

Late-Stage Pipeline

16%

7 trials in Phase 3/4

Results Transparency

38%

9 of 24 completed with results

Key Signals

9 with results92% success

Data Visualizations

Phase Distribution

32Total
Not Applicable (4)
Early P 1 (2)
P 1 (13)
P 2 (6)
P 3 (6)
P 4 (1)

Trial Status

Completed24
Recruiting10
Unknown5
Not Yet Recruiting2
Terminated2
Active Not Recruiting1

Trial Success Rate

92.3%

Benchmark: 86.5%

Based on 24 completed trials

Clinical Trials (45)

Showing 20 of 20 trials
NCT03816345Phase 1RecruitingPrimary

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

NCT00977977Phase 2Recruiting

Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

NCT00943514Recruiting

Natural History of Bronchiectasis

NCT07523282Phase 1Not Yet RecruitingPrimary

Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases

NCT07366866Phase 1RecruitingPrimary

A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci136 in Healthy Adults.

NCT01280825Recruiting

The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing

NCT00716066Phase 2Active Not RecruitingPrimary

Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases

NCT06817889Phase 2Recruiting

Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals

NCT06827457Phase 1CompletedPrimary

A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci120 in Healthy Adults.

NCT06488209Phase 1Completed

Single and Multiple Ascending Dose Study in Healthy Participants and Participants With an Autoimmune Disease

NCT04751396Recruiting

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

NCT06004349Recruiting

Autoimmune and Autoinflammatory Genetics Study

NCT06993493Not ApplicableRecruitingPrimary

Autologous CD19CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases

NCT06983964Not ApplicableRecruitingPrimary

Safety and Efficacy of CD19 CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases

NCT06633042Phase 1Not Yet RecruitingPrimary

The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD

NCT02263703Phase 3CompletedPrimary

Immunogenicity of HPV Vaccine in Immunosuppressed Children

NCT02647866Phase 2Completed

Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis

NCT05894707Phase 1UnknownPrimary

Evaluate the Safety and Tolerability of SCT650C in Healthy Volunteers

NCT00114530Phase 2Completed

Scleroderma: Cyclophosphamide or Transplantation

NCT03186794Not ApplicableTerminated

Aerobic Exercise in Women With Systemic Lupus Erythematosus

Scroll to load more

Research Network

Activity Timeline